Baxter International (BAX) : 11 analysts are covering Baxter International (BAX) and their average rating on the stock is 2.94, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 9 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Baxter International (BAX) : The most positive equity analysts on Baxter International (BAX) expects the shares to touch $60, whereas, the least positive believes that the stock will trade at $47 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $50.57 with an expected fluctuation of $4.54 from the mean.
Company shares have received an average consensus rating of Hold for the current week Also, UBS maintains their rating on the shares of Baxter International (NYSE:BAX). The current rating of the shares is Neutral. Equity Analysts at the Firm raises the price target to $50 per share from $48 per share. The rating by the firm was issued on July 28, 2016.
Baxter International (NYSE:BAX): stock was range-bound between the intraday low of $45.77 and the intraday high of $46.13 after having opened at $45.85 on Wednesdays session. The stock finally closed in the red at $45.85, a loss of -0.11%. The stock remained in the red for the whole trading day. The total traded volume was 3,992,677 shares. The stock failed to cross $46.13 in Wednesdays trading. The stocks closing price on Thursday was $45.95.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.